Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954412 | 1.00 | CA1 (0.48) | CA1CA2ENPP2CA12CA7 | |
| SCHEMBL2552487 | 0.85 | ESR2 (0.47) | CA1CA2ENPP2ALDH1A1HPGD | |
| SCHEMBL29953552 | 0.80 | NQO1 (0.48) | ALDH1A1PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL29956721 | 0.79 | ABL1 (0.34) | CA1CA2ENPP2MEN1KMT2A | |
| SCHEMBL2718786 | 0.75 | CACNA1I (0.33) | CA1CA2ENPP2ALDH1A1F2 | |
| SCHEMBL2239434 | 0.75 | FYN (0.51) | ENPP2CLK4 | |
| Hydrochloric Acid SCHEMBL2242352 | 0.73 | FYN (0.50) | ENPP2CLK4 | |
| SCHEMBL21801745 | 0.72 | CA1 (0.41) | CA1CA2ENPP2CA12CA7 | |
| SCHEMBL200776 | 0.71 | CCR1 (0.48) | CA2ALDH1A1MAPT | |
| SCHEMBL29958138 | 0.71 | CCR1 (0.48) | CA2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352023-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-10-24 | — | — | US | disclosed |
| WO-2024208315-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-10-10 | — | — | WO | disclosed |
| US-12037338-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-07-16 | — | — | US | disclosed |
| EP-3842436-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | SK BIOPHARMACEUTICALS CO LTD (KR) | 2023-11-08 | — | — | EP | disclosed |
| US-20210300933-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-09-30 | — | — | US | disclosed |
| EP-3842436-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | SK Biopharmaceuticals Co., Ltd. (KR) | 2021-06-30 | — | — | EP | disclosed |
| US-11046702-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-06-29 | — | — | US | disclosed |
| EP-3262047-B1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2021-01-06 | — | — | EP | disclosed |
| US-20200277298-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-09-03 | — | — | US | disclosed |
| US-10689357-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof | NORTHEASTERN UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2619179-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2013079425-A1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| WO-2012038944-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689357-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof | NAAA, NAT1, ACHE | CA1 809/4885CA2 1932/4885ENPP2 235/4885 |
| US-20200277298-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GRM5, GRIK5, GRM1 | CA1 3033/4885CA2 656/4885ENPP2 1972/4885 |
| US-20210300933-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GRM5, GRIK5, GRM1 | CA1 3033/4885CA2 656/4885ENPP2 1972/4885 |
| US-11046702-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | GRM5, GRIK5, GRM1 | CA1 3033/4885CA2 656/4885ENPP2 1972/4885 |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | CA1 2861/4885CA2 3768/4885ENPP2 326/4885 |
| US-20240352023-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GRM5, GRIK5, GRM1 | CA1 3033/4885CA2 656/4885ENPP2 1972/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | CA1 4002/4885CA2 4224/4885ENPP2 1180/4885 |
| US-12037338-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | GRM5, GRIK5, GRM1 | CA1 3033/4885CA2 656/4885ENPP2 1972/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | CA1 2861/4885CA2 3768/4885ENPP2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.